1. 243P Skin biopsies for pharmacodynamic studies of tebentafusp: A novel bispecific molecule against the melanocytic antigen gp100. (December 2022) Authors: Stäger, R.; Tastanova, A.; Ramelyte, E.; Levesque, M.P.; Dummer, R.; Meier-Schiesser, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. (September 2015) Authors: Long, G.V.; Dummer, R.; Ribas, A.; Puzanov, I.; Michielin, O.; Vanderwalde, A.; Andtbacka, R.H.I.; Cebon, J.; Fernandez, E.; Malvehy, J.; Olszanski, A.J.; Gajewski, T.F.; Kirkwood, J.M.; Gause, C.; Chen, L.; Kaufman, D.R.; Chou, J.; Hodi, F.S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. (September 2015) Authors: Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroyakovskiy, D.; Lichinitser, M.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsova, I.; Hauschild, A.; Mookerjee, B.; Legos, J.; Schadendorf, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. (September 2015) Authors: Dummer, R.; Sandhu, S.; Hassel, J.C.; Muñoz, E.; Berking, C.; Gesierich, A.; Ascierto, P.A.; Esposito, O.; Carter, K.; Antona, V.; Radhakrishnan, R.; Cui, X.; Caponigro, G.; Jaeger, S.; Demuth, T.; Miller Jr, W.H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE). (September 2015) Authors: Middleton, M.; Dalle, S.; Corrie, P.; Loquai, C.; Terheyden, P.; Kähler, K.C.; Meiss, F.; Board, R.; Arance, A.M.; Gutzmer, R.; Tarhini, A.; Dummer, R.; Ernst, S.; Richtig, E.; Wolter, P.; Bulger, K.; Kotapati, S.; Le, T.K.; Brokaw, J.; Abernethy, A.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study. (September 2015) Authors: Hansson, J.; Bartley, K.; Grob, J.J.; Kuntsfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Licitra, L.; Dutriaux, C.; Jouary, T.; Meyer, N.; Guillot, B.; Dummer, R.; Fife, K.; Ernst, D.S.; Yim, Y.M.; Williams, S.; Fittipaldo, A.; Basset-Seguin, N.; Hauschild, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study. (September 2015) Authors: Hauschild, A.; Hansson, J.; Grob, J.J.; Kunstfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Dummer, R.; Licitra, L.; Fife, K.; Ernst, D.S.; Dutriaux, C.; Jouary, T.; Meyer, N.; Guillot, B.; Williams, S.; Tandon, M.; Hou, J.; Basset-Seguin, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S681 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). (September 2015) Authors: Grob, J.J.; Amonkar, M.; Karaszewska, B.; Schachter, J.; Dummer, R.; Mackiewicz, A.; Stroiakovski, D.; Drucis, K.; Grange, F.; Chiarion-Sileni, V.; Rutkowski, P.; Lichinitser, M.; Levchenko, E.; Wolter, P.; Hauschild, A.; Long, G.V.; Sun, P.; McDowell, D.O.; Mookerjee, B.; Robert, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria. (September 2015) Authors: Dummer, R.; Sondak, V.; Grichnik, J.; Schwartz, L.; Guminski, A.; Gutzmer, R.; Yi, T.; Trylesinski, A.; Sellami, D.; Migden, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 3349 Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. (September 2015) Authors: Otsuka, A.; Dreier, J.; Cheng, P.; Nägeli, M.; Levesque, M.P.; Dummer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S685 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗